The Dermatology Digest

DECEMBER 21, 2023

The two distribution agreements for the Evolysse /Estyme fillers portfolio will grant Evolus the ability to offer filler solutions to cover mid-face, nasolabial folds, and lip indications in Europe plus an eye product line in the U.S. We are extremely excited to expand our partnership with Evolus beyond the U.S. to now include the U.K.

Marketing 36

Marketing Sales Branding Portfolios 36

The Dermatology Digest

DECEMBER 21, 2023

The two distribution agreements for the Evolysse /Estyme fillers portfolio will grant Evolus the ability to offer filler solutions to cover mid-face, nasolabial folds, and lip indications in Europe plus an eye product line in the U.S. We are extremely excited to expand our partnership with Evolus beyond the U.S. to now include the U.K.

Marketing 36

Marketing Sales Branding Portfolios 36

Aesthetics Advisor

SEPTEMBER 15, 2023

Glenmark Pharmaceuticals has signed a partnership with Canadian company SaNOtize Research & Development Corp., For a full list of Marinomed’s portfolio of Carragelose® containing nasal sprays and oral products, please visit [link] , for a list of scientific publications on Carragelose®, [link].

Hospital 69

Hospital Clinic Marketing Medical 69

The Dermatology Digest

MARCH 27, 2025

Alumis is also eligible to receive tiered royalties ranging from the low double-digits into the twenties onaggregate net sales of ESK-001 in Japan. ESK-001 will be an important addition to the Kaken portfolio of novel therapeutics for dermatology conditions.

Pharmaceutical 36

Pharmaceutical Portfolios Clinic Safety 36